BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Mar 09, 2015
 |  BioCentury  |  Finance

Can AbbVie Imbruv on this?

Tracking Imbruvica payouts to Pharmacyclics, prior owners

While the future of Imbruvica ibrutinib as a cancer treatment is yet to be writ, it has definitely paid to own a piece of the action along the way. The drug, which has generated a little over half a billion in sales so far, has generated at least $13.7 billion in cash for its current and erstwhile owners.

The question is whether the pixie dust will carry over to AbbVie Inc. (NASDAQ:ABBV), which last week agreed to acquire Imbruvica's current owner, Pharmacyclics Inc. (NASDAQ:PCYC), for $21 billion, including about $12.2 billion in cash and $8.8 billion in stock.


Read the full 493 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >